Effects of Pregnane X Receptor (PXR) Activation on Human Glucose, Lipid and Hormone Homeostasis
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial is designed to study the effects of pregnane X receptor activator
rifampicin on the glucose, lipid and hormone homeostasis in healthy volunteers. The main
hypothesis is that rifampicin raises postprandial glucose studied with oral glucose tolerance
test. The study is a non-randomized, one-phase, open-label trial. Twelve subjects will be
given 600 mg of rifampicin a day for a week. The main outcome measures are the changes in the
glucose and insulin levels during oral glucose tolerance test.